News › ZEISS • pres­ents inte­gra­ted work­flow advance­ments at AAO

The latest solu­ti­ons from ZEISS help doc­tors advance oph­thal­mic care with new ways to maxi­mize cli­ni­cal effi­ci­ency and performance

Medi­cal Tech­no­logy Seg­ment of ZEISS will pre­sent its latest inte­gra­ted dia­gno­stic and sur­gi­cal advance­ments at the 2020 Ame­ri­can Aca­demy of Ophthalmology’s (AAO) Annual Mee­ting taking place vir­tually from Nov. 13–15. ZEISS will also be hos­ting mul­ti­ple indus­try show­ca­ses and edu­ca­tio­nal ses­si­ons with renow­ned experts throug­hout the event.

“We are con­ti­nuing to expand our port­fo­lio of inte­gra­ted work­flow solu­ti­ons that span across the full con­ti­nuum of care; retina, glau­coma, cata­ract, and cor­neal refrac­tive,” says Lud­win Monz, Pre­si­dent and CEO of Carl Zeiss Medi­tec. “Digi­ta­liza­tion pres­ents many oppor­tu­ni­ties to improve tre­at­ment out­co­mes and increase the effi­ci­ency of cli­ni­cal work­flows. Our goal is to pro­vide doc­tors and sur­ge­ons with advan­ced solu­ti­ons to help them care for their pati­ents in the best pos­si­ble way,” adds Euan S. Thom­son, Pre­si­dent of Oph­thal­mic Devices and Head of the Digi­tal Busi­ness Unit for Carl Zeiss Meditec.

Retina and Glau­coma Work­flows – ZEISS inte­gra­ted solu­ti­ons trans­form cri­ti­cal infor­ma­tion by com­bi­ning, gathe­ring, and asso­cia­ting data which aids phy­si­ci­ans with inter­pre­ting, ana­ly­zing, and mana­ging pro­gres­sion for opti­mi­zed indi­vi­dual assess­ments. »The pro­li­fe­ra­tion of new and more advan­ced ima­ging devices, like the CIRRUS® 6000 OCT and CLARUS® ultra-wide­field camera, has dra­ma­ti­cally enhan­ced the dia­gno­stic capa­bi­li­ties of retina spe­cia­lists by pro­vi­ding easy cap­ture of num­e­rous com­ple­men­tary ima­ging moda­li­ties,“ said Eric W. Schnei­der, MD, a retina phy­si­cian at Ten­nes­see Retina (Ten­nes­see, USA).

Cata­ract Work­flow – ZEISS has fully inte­gra­ted VERACITY Surgical1 with ZEISS devices, inclu­ding the Cen­tral Topo­gra­phy and new Bar­rett True‑K TK (non-toric and toric) for­mula of the IOL­Mas­ter® 700, as well as auto­ma­tic toric IOL implan­ta­tion sup­port func­tions of CALLISTO® eye. This total pre­mium cata­ract work­flow inte­gra­tion with ZEISS VERACITY Sur­gi­cal boosts pro­duc­ti­vity so sur­ge­ons can deli­ver care to more pati­ents in less time. “I think there are quite a few cata­ract sur­ge­ons out there who could increase their sur­gi­cal volume by using VERACITY Sur­gi­cal to ensure their sur­gi­cal work­flow is seam­less and effi­ci­ent,” said Bran­don D. Ayres, board-cer­ti­fied oph­thal­mo­lo­gist at the Wills Eye Hos­pi­tal (Penn­syl­va­nia, USA). “Not only will it help increase sur­gi­cal volume, but it will decrease admi­nis­tra­tive busy work inside of pati­ent charts.”

Cor­neal Refrac­tive Work­flow – In the U.S. mar­ket, the use of the Len­ti­cule Extra­c­tion with SMILE® from ZEISS is gro­wing more than 35 per­cent over last year against the U.S. mar­ket trend. For the first time in Octo­ber 2020, more than 1 mil­lion tre­at­ments with SMILE® were per­for­med in a sin­gle year glo­bally. »I had Pho­to­re­frac­tive kera­tec­tomy (PRK) years ago prior to deploy­ing to Iraq. If given the choice today, I would defi­ni­tely choose to get SMILE®,” said Dr. Bruce A. Rivers, MD, medi­cal direc­tor of Envue Eye & Laser Cen­ter (Mary­land, USA). “It’s the best of both worlds – the heal­ing of LASIK with the sta­bi­lity of PRK because there is no flap.« ZEISS is curr­ently con­duc­ting a U.S. mili­tary study for the Len­ti­cule Extra­c­tion with SMILE® from ZEISS at three Depart­ment of Defense (DOD) sites. Addi­tio­nally, with eight sites now enrol­led, the cli­ni­cal trial with the MEL® 902 exci­mer laser from ZEISS is under­way in the U.S. and recrui­ting all indi­ca­ti­ons inclu­ding myo­pia, hyper­opia and mixed astigmatism.

ZEISS will kick off AAO 2020 Vir­tual with its Oph­thal­mic Vir­tual Expe­ri­ence on Nov. 12, and will con­ti­nue to offer edu­ca­tio­nal ses­si­ons, as well as an inter­ac­tive vir­tual show­room, through Nov. 15.

1 ZEISS VERACITY Sur­gi­cal is available in the U.S. only.
2 ZEISS VisuMax-MEL 90 com­bi­na­tion not for sale in the U.S., not cleared/approved in U.S.

Brief Pro­file

Carl Zeiss Medi­tec AG (ISIN: DE 0005313704), which is lis­ted on the MDAX and TecDAX of the Ger­man stock exch­ange, is one of the world’s lea­ding medi­cal tech­no­logy com­pa­nies. The Com­pany sup­plies inno­va­tive tech­no­lo­gies and appli­ca­tion-ori­en­ted solu­ti­ons desi­gned to help doc­tors improve the qua­lity of life of their pati­ents. The Com­pany offers com­plete solu­ti­ons, inclu­ding implants and con­su­ma­bles, to dia­gnose and treat eye dise­a­ses. The Com­pany crea­tes inno­va­tive visua­liza­tion solu­ti­ons in the field of micro­sur­gery. With 3,232 employees (as of 30 Sep­tem­ber 2019) world­wide, the Group gene­ra­ted reve­nue of €1,459.3m in fis­cal year 2018/19 (as of 30 September).

The Group’s head office is loca­ted in Jena, Ger­many, and it has sub­si­dia­ries in Ger­many and abroad; more than 50 per­cent of its employees are based in the USA, Japan, Spain and France. The Cen­ter for Appli­ca­tion and Rese­arch (CARIn) in Banga­lore, India and the Carl Zeiss Inno­va­tions Cen­ter for Rese­arch and Deve­lo­p­ment in Shang­hai, China, streng­then the Company’s pre­sence in these rapidly deve­lo­ping eco­no­mies. Around 41 per­cent of Carl Zeiss Medi­tec AG’s shares are in free float. The remai­ning approx. 59 per­cent are held by Carl Zeiss AG, one of the world’s lea­ding groups in the opti­cal and opto­elec­tro­nic industries.

For fur­ther infor­ma­tion visit: www.zeiss.com/med

Cont­act for investors

Sebas­tian Frericks
Direc­tor Inves­tor Relations
Carl Zeiss Medi­tec AG
+49 3641 220–116
moc.ssiez@cetidem.srotsevni

Cont­act for the press

Lau­rie Ferguson
Head of Glo­bal Com­mu­ni­ca­ti­ons Oph­thal­mic Devices
Carl Zeiss Meditec
+1 925 719 7825
moc.ssiez@nosugref.eirual